A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines

p21Cip1/WAF1mediates cyclin B1 degradation in response to DNA damage

(2011) Laura D. Gillis et al.   CELL CYCLE

Erratum: Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro

(2011) J Iqbal et al.   LEUKEMIA

p53 binding to the p21 promoter is dependent on the nature of DNA damage

(2010) Ewelina Bodzak et al.   CELL CYCLE

Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A

(2010) Poonam R. Molli et al.   JOURNAL OF CELL BIOLOGY

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

(2010) T. Shimomura et al.   MOLECULAR CANCER THERAPEUTICS

Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2

(2009) Joshua L Andersen et al.   EMBO JOURNAL

Aurora kinase inhibitors in preclinical and clinical testing

(2009) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152

(2009) J Guo et al.   PHARMACOGENOMICS JOURNAL

Aurora-A interacts with Cyclin B1 and enhances its stability

(2008) Lili Qin et al.   CANCER LETTERS

Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells

(2008) Altaf A. Dar et al.   CANCER RESEARCH

Dissecting the role of Aurora A during spindle assembly

(2008) Teresa Sardon et al.   EMBO JOURNAL

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma

(2008) Zhong-Zhe Lin et al.   JOURNAL OF HEPATOLOGY